Payment overview · 2025
General Payments
$21,965.85
166 reported records · 41 companies
Healthcare provider profile · identity verified
Robert Earl Gardner, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Clinical Neurophysiology · CAPE GIRARDEAU, MO · NPI 1649365917
Verified facts
What the public records show
CMS Open Payments records show Robert Earl Gardner, MD received $21,965.85 in general payments during 2025 across 166 reported records.
ABBVIE INC. accounted for 79.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ongentys by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REYVOW as an associated drug or biological on 378 records involving 290 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Reyvow by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mayzent by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17,479.93 | 79.6% | 39 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $1,016.14 | 4.6% | 11 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $264.11 | 1.2% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $252.45 | 1.1% | 8 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $225.13 | 1.0% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $221.69 | 1.0% | 12 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $214.35 | 1.0% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $206.50 | 0.9% | 5 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $190.31 | 0.9% | 6 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $182.77 | 0.8% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $180.73 | 0.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $139.31 | 0.6% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $123.10 | 0.6% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $120.85 | 0.6% | 6 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $98.20 | 0.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $97.42 | 0.4% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $97.24 | 0.4% | 6 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$75.85 | 0.3% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $75.41 | 0.3% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $74.11 | 0.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $65.58 | 0.3% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$57.68 | 0.3% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $55.58 | 0.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.14 | 0.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$41.25 | 0.2% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $35.26 | 0.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.41 | 0.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.69 | 0.1% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $28.06 | 0.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.27 | 0.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.70 | 0.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.57 | 0.1% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $21.54 | 0.1% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $20.75 | 0.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.46 | 0.1% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $18.47 | 0.1% | 1 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $18.27 | 0.1% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $18.20 | 0.1% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $15.08 | 0.1% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $14.38 | 0.1% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $12.91 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,931.25 | 7 |
| Food and Beverage | $3,651.93 | 150 |
| Travel and Lodging | $857.67 | 6 |
| Consulting Fee | $525.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17,305.17 | 29 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $2,737.80 | 8 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $1,016.14 | 11 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $264.11 | 6 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $252.45 | 8 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $225.13 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $219.37 | 11 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $214.35 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $190.31 | 6 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $182.77 | 5 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| XYREM Normalized: xyrem |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $139.31 | 3 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $138.18 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $120.85 | 6 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $93.00 | 8 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $82.40 | 5 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $75.66 | 3 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $75.41 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $65.58 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $57.91 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $57.68 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $55.58 | 2 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $41.25 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.51 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $35.26 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $34.65 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.17 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $28.69 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| QALSODY Normalized: qalsody |
Drug | Biogen, Inc. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | HOSPIRA, INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | HOSPIRA, INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $12.91 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $2.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
120 | 20 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | REYVOW open payments reported associated product |
CMS Open Payments — General Payments 378 supporting records · 290 recipient NPIs · example record 1186470979 |
Reyvow · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 274 | 57 |
| Topiramate | Topiramate | 248 | 34 |
| Levetiracetam | Levetiracetam | 231 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 225 | 48 |
| Donepezil Hcl | Donepezil Hcl | 182 | 35 |
| Sumatriptan Succinate | Sumatriptan Succinate | 149 | 28 |
| Aimovig Autoinjector | Erenumab-Aooe | 137 | 18 |
| Ubrelvy | Ubrogepant | 120 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 117 | 30 |
| Memantine Hcl | Memantine Hcl | 117 | 24 |
| Lamotrigine | Lamotrigine | 95 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 86 | 17 |
| Rizatriptan | Rizatriptan Benzoate | 82 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 11 |
| Clonazepam | Clonazepam | 70 | suppressed |
| Modafinil | Modafinil | 66 | 12 |
| Propranolol Hcl | Propranolol Hcl | 64 | 13 |
| Baclofen | Baclofen | 63 | 12 |
| Lacosamide | Lacosamide | 63 | suppressed |
| Primidone | Primidone | 63 | 16 |
| Pregabalin | Pregabalin | 59 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 52 | suppressed |
| Briviact | Brivaracetam | 46 | suppressed |
| Carbamazepine | Carbamazepine | 45 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 45 | suppressed |
| Qulipta | Atogepant | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Teriflunomide | Teriflunomide | 37 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 36 | suppressed |
| Xcopri | Cenobamate | 36 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Prednisone | Prednisone | 35 | suppressed |
| Carbamazepine Er | Carbamazepine | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 25 | suppressed |
| Ongentys | Opicapone | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Nourianz | Istradefylline | 21 | suppressed |
| Reyvow | Lasmiditan Succinate | 21 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 21 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Fycompa | Perampanel | 18 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Mayzent | Siponimod | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Carbatrol | Carbamazepine | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Felbatol | Felbamate | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Glatopa | Glatiramer Acetate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21,965.85 · 166 records | ABBVIE INC. | ACTHAR, AJOVY, AMPYRA, AUSTEDO XR, BOTOX, BRIUMVI, Briviact, CREXONT, CUTAQUIG, Dysport, Gamunex-C, Hizentra, INBRIJA, INFINITY, INGREZZA, KESIMPTA, KISUNLA, LUMRYZ, Leqembi, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PERCEPT PC BRAINSENSE, PONVORY, QALSODY, QULIPTA, REXULTI, SKYCLARYS, SPINRAZA, SPRAVATO, Sunosi, Symbravo, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VYEPTI, VYVGART HYTRULO, WAINUA, WAKIX, WatchPATONE, XYREM, XYWAV, Xeomin, ZAVZPRET, ZEPBOUND, ZEPOSIA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error